Tighter Standards Ahead for Generic Epilepsy Drugs

Studies are underway that may lead the FDA to stiffen its bioequivalence rules for generic anti-epileptic drugs (AEDs). Dr. Michael Privitera, a neurologist at the UC Gardner Neuroscience Institute’s Epilepsy Center, explains that after some hesitation the FDA has agreed that studies are necessary.

Read the story here>>

Media Outlet:
Med Page Today

This entry was posted in Articles. Bookmark the permalink. Both comments and trackbacks are currently closed.

Click Here to learn about our most recent COVID-19 updates including vaccine information, visitor restrictions, testing, and more.